MMA not harming patients

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 12
Volume 16
Issue 12

Cancer patients receiving chemotherapy have not noticed a restriction in their access to treatment following the enactment of the Medicare Prescription Drug Improvement and Modernization Act of 2003

Cancer patients receiving chemotherapy have not noticed a restriction in their access to treatment following the enactment of the Medicare Prescription Drug Improvement and Modernization Act of 2003 (MMA), despite the act's significant reduction in government reimbursement to oncologists, according to a new study from the Duke Clinical Research Institute (Cancer 110:2304-2312, 2007).

The researchers examined results of 1,421 surveys completed via the Internet by 684 patients who had received chemotherapy prior to MMA enactment and 737 who were treated afterward.

"The majority of patients in each group reported being either satisfied or very satisfied with the care they received from their oncologists," said senior investigator Kevin Schulman, MD, director of the DCRI's Center for Clinical and Genetic Economics.

Further, there was no difference in the amount of time from diagnosis to treatment or in average travel time.

"When the act was passed, many were concerned about the consolidation of services it might necessitate, such as the moving of chemotherapy services to hospital rather than outpatient settings and the elimination of staff positions," said lead author Joelle Friedman, a DCRI researcher. "They were afraid these changes would affect patients' access to care, but our study showed these concerns turned out to be largely unwarranted."

Recent Videos
Ronald Bleday, MD, stated that before standardizing a stepwise approach to treating surgical pain, providers might have overtreated patients with opioids.
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.
1 expert is featured in this series.
Conducting trials safely within a community setting lies at the heart of a successful collaboration between Northwell Health and START.
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
The expertise of START's network may streamline the availability of clinical trial enrollment and novel treatment options among patients with cancer.
Related Content